Illumina lowers Outlook due to China sales ban
Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a ...
Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...
The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country.
China accounts for about 7% of Illumina's sales. Gene sequencers help determine the sequence of DNA or RNA, allowing scientists to study genetic variations associated with diseases and diagnose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results